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8.1 Components, product list and catalogue numbers for media and compounds used  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound DDU No Source 
A: Buspirone DDD00071691 Sigma Aldrich 
B: Clozapine DDD00071710 Sigma Aldrich 
C: Primaquine DDD00071792 Sigma Aldrich 
D: Trifluoperazine DDD00071950 Selleck Chemicals 
E: Naftopidil DDD00072552 TCI 
Compound NCM 
(mM) 
CM (mM) Source Catalogue No 
CaCl2 1.8 1.8 Sigma-Aldrich C3306 - 100 
KCl 5.4 5.4 Sigma-Aldrich P5405 – 250g 
MgSO4.7H2O 0.8 0.8 Sigma-Aldrich M2773 - 500g 
Sodium chloride 116.4 116.4 Sigma-Aldrich S5886 – 1Kg 
NaH2PO4.2H2O 1.0 1.0 Sigma-Aldrich 71505 - 250g 
D- glucose 5.55 5.55 Sigma-Aldrich G6152 – 500g 
Sodium lactate 41.75 25 Sigma-Aldrich L7900 – 100ml 
Sodium pyruvate 2.73 2.73 Sigma-Aldrich P2256 – 25g 
HEPES 25 - Sigma-Aldrich H3375 – 1Kg 
Sodium 
bicarbonate 
- 26 Sigma-Aldrich S5761 -500g 
BSA 0.3% 0.3% Sigma-Aldrich A3059 – 100g 
Compound Source Catalogue No 
DMSO Sigma-Aldrich 673439 
PureSperm 40% and 80% Hunter Scientific PS40-100 
PS80-100 
SAGE Gamete buffer Origio ART-1005 
Quinns Advantage 
Fertilisation Medium 
Origio ART-1020 
Human Serum Albumin 
(HSA) 
Origio  ART-3001 
Percoll Sigma-Aldrich P1644 
Methylcellulose Sigma-Aldrich M0512 
PSA FITC Sigma-Aldrich L0770 
TO-PRO3 Life Technologies T3605 
Calcium Ionophore 
(A23187) 
Sigma-Aldrich C7522 
Progesterone Sigma-Aldrich P0130-25G 
5 
 
F: Diphenoxylate DDD00203482 Sequoia Research 
Products 
G: MK886 DDD00203517 Tocris 
H: Iloperidone DDD00771622 Selleck Chemicals 
I: Nebivolol DDD00771630 Selleck Chemicals 
J: Gepirone DDD00853764 Sequoia Research 
Products 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8.1 Identification of compounds and the product source for media which were utilised in 
all experiments conducted within this project.  
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8.2 CASA motility analysis of 10 compounds 
8.2.1 Compound A 30μM 80% 
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% Linearity Drug A
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8.2.2 Compound B 30μM 80% 
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Figure 8.1:  80% sperm cell fraction motility screen using 30µM 
drug A. No. of donors = 15. Each motility parameter was compared 
using ANOVA of control (Cont), DMSO and drug A groups at Time 
0 minutes (T0), Time 15 minutes (T15) and Time 30 minutes (T30). 
A) Average % progressive cells – no statistically significant 
difference. B) Average % rapid cells – no statistically significant 
difference. C) Average VAP – no statistically significant difference. 
D) Average VCL – no statistically significant difference. E) Average 
ALH – no statistically significant difference. F) Average % 
straightness – no statistically significant difference. G) Average % 
linearity – no statistically significant difference. Error bars indicate 
standard error of the mean (SEM). 
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ALH Drug B
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8.2.3 Compound C 30μM 80% 
% Progression Drug C
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Figure 8.2:  80% sperm cell fraction motility screen using 30µM 
drug B. No. of donors = 14. Each motility parameter was compared in 
the control (Cont), DMSO and drug B groups at Time 0 minutes (T0), 
Time 15 minutes (T15) and Time 30 minutes (T30). A) Average % 
progressive cells – no statistically significant difference. B) Average 
% rapid cells – no statistically significant difference. C) Average VAP 
– no statistically significant difference. D) Average VCL – no 
statistically significant difference. E) Average ALH – no statistically 
significant difference. F) Average % straightness – no statistically 
significant difference. G) Average % linearity – no statistically 
significant difference. Error bars indicate standard error of the mean 
(SEM). 
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Figure 8.3:  80% sperm cell fraction motility screen using 30µM drug C. No. of donors = 14. Each 
motility parameter was compared in the control (Cont), DMSO and drug C groups at Time 0 minutes (T0), 
Time 15 minutes (T15) and Time 30 minutes (T30). A) Average % progressive cells – no statistically 
significant difference. B) Average % rapid cells – no statistically significant difference. C) Average VAP – no 
statistically significant difference D) Average VCL – no statistically significant difference E) Average ALH – 
no statistically significant difference F) Average % straightness – no statistically significant difference G) 
Average % linearity – no statistically significant difference. Error bars indicate standard error of the mean 
(SEM). 
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8.2.4 Compound D 30μM 80% 
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8.2.5 Compound E 30μM 80% 
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Figure 8.4:  80% sperm cell fraction motility screen using 
30µM drug D. No. of donors = 13. Each motility parameter was 
compared using ANOVA of control (Cont), DMSO and drug D 
groups at Time 0 minutes (T0), Time 15 minutes (T15) and Time 
30 minutes (T30). A) Average % straightness – no statistically 
significant difference. B) Average % linearity – no statistically 
significant difference. C) Average ALH – T0: no significant 
difference. T15: Control + drug D - * (P=0.0362). T30: no 
significant difference. Error bars indicate standard error of the 
mean (SEM). 
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% Progression Drug E
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Figure 8.5:  80% sperm cell fraction motility screen using 
30µM drug E. No. of donors = 13. Each motility parameter was 
compared using ANOVA of control (Cont), DMSO and drug E 
groups at Time 0 minutes (T0), Time 15 minutes (T15) and 
Time 30 minutes (T30). A) Average % motile cells – no 
statistically significant difference. B) Average % Hyperactivated 
cells – no statistically significant difference. C) Average % 
progressive cells – no statistically significant difference. D) 
Average % straightness – no statistically significant difference 
E) Average % linearity – no statistically significant difference. 
Error bars indicate standard error of the mean (SEM). 
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8.2.6 Compound F 30μM 80% 
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8.2.7 Compound G 30μM 80% 
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Figure 8.6:  80% sperm cell fraction motility screen using 
30µM drug F. No. of donors = 14. Each motility parameter was 
compared in the control (Cont), DMSO and drug F groups at Time 
0 minutes (T0), Time 15 minutes (T15) and Time 30 minutes 
(T30). A) Average % progressive cells – no statistically significant 
difference. B) Average % rapid cells – no statistically significant 
difference. C) Average VAP – no statistically significant 
difference. D) Average VCL – no statistically significant 
difference. E) Average ALH – no statistically significant 
difference. F) Average % straightness – no statistically significant 
difference. G) Average % linearity – no statistically significant 
difference. Error bars indicate standard error of the mean (SEM). 
Figure 8.7:  80% sperm cell fraction motility screen using 30µM drug G. No. of donors = 13. 
Each motility parameter was compared using ANOVA of control (Cont), DMSO and drug G groups at 
Time 0 minutes (T0), Time 15 minutes (T15) and Time 30 minutes (T30). A) Average % motile cells 
– no statistically significant different. B) Average % progressive cells – no statistically significant 
difference. C) Average % straightness – no statistically significant difference. D) Average % linearity 
– no statistically significant difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.8:  80% sperm cell fraction motility screen using 30µM 
drug H. No. of donors = 13. Each motility parameter was compared in 
the control (Cont), DMSO and drug H groups at Time 0 minutes (T0), 
Time 15 minutes (T15) and Time 30 minutes (T30). A) Average % 
progressive cells – no statistically significant difference. B) Average % 
rapid cells – no statistically significant difference. C) Average VAP – 
no statistically significant difference. D) Average VCL – no 
statistically significant difference. E) Average ALH – no statistically 
significant difference. F) Average % straightness – no statistically 
significant difference. G) Average % linearity – no statistically 
significant difference. Error bars indicate standard error of the mean 
(SEM). 
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Figure 8.9:  80% sperm cell fraction motility screen using 30µM drug I. No. of donors = 12. Each motility parameter was 
compared in the control (Cont), DMSO and drug I groups at Time 0 minutes (T0), Time 15 minutes (T15) and Time 30 
minutes (T30).  A) Average % Hyperactivated cells – no statistically significant difference. B) Average VAP – no statistically 
significant difference. C) Average VCL – no statistically significant difference. D) Average ALH – no statistically significant 
difference. E) Average % straightness – no statistically significant difference. F) Average % linearity – no statistically 
significant difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.10:  80% sperm cell fraction motility screen using 30µM 
drug J. No. of donors = 12. Each motility parameter was compared in 
the control (Cont), DMSO and drug J groups at Time 0 minutes (T0), 
Time 15 minutes (T15) and Time 30 minutes (T30). A) Average % 
progressive cells – no statistically significant difference. B) Average 
% rapid cells – no statistically significant difference. C) Average VAP 
– no statistically significant difference. D) Average VCL – no 
statistically significant difference. E) Average ALH – no statistically 
significant difference. F) Average % straightness – no statistically 
significant difference. G) Average % linearity – no statistically 
significant difference. Error bars indicate standard error of the mean 
(SEM). 
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Figure 8.11:  40% sperm cell fraction motility screen using 30µM drug A. No. of donors = 9. Each motility 
parameter was compared in the control (Cont), DMSO and drug A groups at Time 0 minutes (T0), Time 15 minutes 
(T15) and Time 30 minutes (T30). A) Average % rapid cells – no statistically significant difference. B) Average VAP 
– no statistically significant difference. C) Average VCL – no statistically significant difference. D) Average ALH – 
no statistically significant difference. E) Average % straightness – no statistically significant difference. F) Average 
% linearity – no statistically significant difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.12:  40% sperm cell fraction motility screen using 30µM drug B. No. of donors = 12. Each motility 
parameter was compared in the control (Cont), DMSO and drug B groups at Time 0 minutes (T0), Time 15 minutes 
(T15) and Time 30 minutes (T30). A) Average % rapid cells – no statistically significant difference. B) Average 
VAP – no statistically significant difference. C) Average VCL – no statistically significant difference. D) Average 
ALH – no statistically significant difference. E) Average % straightness – no statistically significant difference. F) 
Average % linearity – no statistically significant difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.13:  40% sperm cell fraction motility screen using 30µM drug C. No. of donors = 14. Each motility parameter 
was compared in the control (Cont), DMSO and drug C groups at Time 0 minutes (T0), Time 15 minutes (T15) and Time 30 
minutes (T30). A) Average % rapid cells – no statistically significant difference. B) Average VAP – no statistically significant 
difference. C) Average VCL – no statistically significant difference. D) Average ALH – no statistically significant difference. 
E) Average % straightness – no statistically significant difference. F) Average % linearity – no statistically significant 
difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.14:  40% sperm cell fraction motility screen using 30µM 
drug D. No. of donors = 12. Each motility parameter was compared in 
the control (Cont), DMSO and drug D groups at Time 0 minutes (T0), 
Time 15 minutes (T15) and Time 30 minutes (T30). A) Average % rapid 
cells – no statistically significant difference. B) Average VCL – no 
statistically significant difference. C) Average ALH – no statistically 
significant difference. D) Average % straightness – no statistically 
significant difference. E) Average % linearity – no statistically significant 
difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.15:  40% sperm cell fraction motility screen using 30µM 
drug E. No. of donors = 12. Each motility parameter was compared in 
the control (Cont), DMSO and drug E groups at Time 0 minutes (T0), 
Time 15 minutes (T15) and Time 30 minutes (T30). A) Average % rapid 
cells – no statistically significant difference. B) Average VCL – no 
statistically significant difference. C) Average ALH – no statistically 
significant difference. D) Average % straightness – no statistically 
significant difference. E) Average % linearity – no statistically significant 
difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.16:  40% sperm cell fraction motility screen using 30µM drug F. No. of donors = 14. Each motility 
parameter was compared in the control (Cont), DMSO and drug F groups at Time 0 minutes (T0), Time 15 minutes (T15) 
and Time 30 minutes (T30). A) Average VAP of cells – no statistically significant difference. B) Average VCL – no 
statistically significant difference. C) Average ALH – no statistically significant difference. D) Average % linearity – no 
statistically significant difference. Error bars indicate standard error of the mean (SEM). 
Figure 8.17:  40% sperm cell fraction motility screen using 30µM drug G. No. of donors = 12. Each motility parameter was 
compared in the control (Cont), DMSO and drug G groups at Time 0 minutes (T0), Time 15 minutes (T15) and Time 30 minutes (T30). 
A) Average % rapid cells – no statistically significant difference. B) Average ALH – no statistically significant difference. C) Average % 
straightness – no statistically significant difference. D) Average % linearity – no statistically significant difference. Error bars indicate 
standard error of the mean (SEM). 
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Figure 8.18:  40% sperm cell fraction motility screen using 30µM drug H. No. of donors = 14. Each motility 
parameter was compared in the control (Cont), DMSO and drug H groups at Time 0 minutes (T0), Time 15 minutes 
(T15) and Time 30 minutes (T30). A) Average % rapid cells – no statistically significant difference. B) Average VAP 
– no statistically significant difference. C) Average VCL – no statistically significant difference. D) Average ALH – no 
statistically significant difference. E) Average % straightness – no statistically significant difference. F) Average % 
linearity – no statistically significant difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.19:  40% sperm cell fraction motility screen using 30µM drug I. No. of donors = 11. Each motility 
parameter was compared using ANOVA of control (Cont), DMSO and drug I groups at Time 0 minutes (T0), Time 15 
minutes (T15) and Time 30 minutes (T30). A) Average % rapid cells – no statistically significant difference. B) Average 
VAP – no statistically significant difference. C) Average VCL – no statistically significant difference. D) Average ALH 
– no statistically significant difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.20:  40% sperm cell fraction motility screen using 30µM drug J. No. of donors = 11. Each motility 
parameter was compared in the control (Cont), DMSO and drug J groups at Time 0 minutes (T0), Time 15 
minutes (T15) and Time 30 minutes (T30). A) Average % rapid cells – no statistically significant difference. B) 
Average VAP – no statistically significant difference. C) Average VCL – no statistically significant difference. 
D) Average ALH – no statistically significant difference. E) Average % straightness – no statistically significant 
difference. F) Average % linearity – no statistically significant difference. Error bars indicate standard error of 
the mean (SEM). 
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Figure 8.21:  40% sperm cell fraction motility screen using 10µM drug C. No. of donors = 4. Each motility 
parameter was compared in the control (Cont), DMSO and drug C groups at Time 0 minutes (T0), Time 15 
minutes (T15) and Time 30 minutes (T30). A) Average % motile cells – no statistically significant different was 
seen. B) Average % progressive cells – no statistically significant difference. C) Average % rapid cells – no 
statistically significant difference. D) Average VAP – no statistically significant difference. E) Average VCL – no 
statistically significant difference. F) Average ALH – no statistically significant difference. G) Average % 
straightness – no statistically significant difference. H) Average % linearity – no statistically significant 
difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.22:  40% sperm cell fraction motility screen using 10µM drug F. No. of donors = 4. Each motility parameter 
was compared in the control (Cont), DMSO and drug F groups at Time 0 minutes (T0), Time 15 minutes (T15) and Time 
30 minutes (T30). A) Average % motile cells – no statistically significant difference. B) Average % progressive cells – no 
statistically significant difference. C) Average % rapid cells – no statistically significant difference. D) Average VAP – 
no statistically significant difference. E) Average VCL – no statistically significant difference. F) Average ALH – no 
statistically significant difference. G) Average % straightness – no statistically significant difference. H) Average % 
linearity – T0: no statistically significant difference. T15: DMSO + drug F - * (P=0.0369). T30: no statistically significant 
difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.23:  40% sperm cell fraction motility screen using 10µM 
drug H. No. of donors = 4. Each motility parameter was compared in 
the control (Cont), DMSO and drug H groups at Time 0 minutes (T0), 
Time 15 minutes (T15) and Time 30 minutes (T30). A) Average % 
rapid cells – no statistically significant difference. B) Average VAP – 
no statistically significant difference. C) Average VCL – no 
statistically significant difference. D) Average ALH – no statistically 
significant difference. E) Average % straightness – no statistically 
significant difference. Error bars indicate standard error of the mean 
(SEM). 
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Figure 8.24:  80% sperm cell fraction motility screen using 10µM 
drug C. No. of donors = 3. Each motility parameter was compared in 
the control (Cont), DMSO and drug C groups at Time 0 minutes 
(T0), Time 15 minutes (T15) and Time 30 minutes (T30). A) 
Average % motile cells – no statistically significant different was 
seen. B) Average % Hyperactivated cells – no statistically significant 
difference. C) Average % progressive cells – no statistically 
significant difference. D) Average % rapid cells – no statistically 
significant difference. E) Average VAP – no statistically significant 
difference. F) Average VCL – no statistically significant difference. 
G) Average ALH – no statistically significant difference. H) Average 
% straightness – no statistically significant difference. I) Average % 
linearity – no statistically significant difference. Error bars indicate 
standard error of the mean (SEM). 
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Figure 8.25:  80% sperm cell fraction motility screen using 10µM 
drug F. No. of donors = 3. Each motility parameter was compared in 
the control (Cont), DMSO and drug F groups at Time 0 minutes (T0), 
Time 15 minutes (T15) and Time 30 minutes (T30). A) Average % 
motile cells – no statistically significant difference. B) Average % 
Hyperactivated cells – no statistically significant difference. C) 
Average % progressive cells – no statistically significant difference. 
D) Average % rapid cells – no statistically significant difference. E) 
Average VAP – no statistically significant difference. F) Average 
VCL – no statistically significant difference. G) Average ALH – no 
statistically significant difference. H) Average % straightness – no 
statistically significant difference. I) Average % linearity – no 
statistically significant difference. Error bars indicate standard error 
of the mean (SEM). 
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Figure 8.26:  80% sperm cell fraction motility screen using 10µM 
drug H. No. of donors = 3. Each motility parameter was compared in the 
control (Cont), DMSO and drug H groups at Time 0 minutes (T0), Time 
15 minutes (T15) and Time 30 minutes (T30). A) Average % motile cells 
– no statistically significant difference. B) Average % Hyperactivated 
cells – no statistically significant difference. C) Average % progressive 
cells – no statistically significant difference. D) Average % rapid cells – 
no statistically significant difference. E) Average VAP – no statistically 
significant difference. F) Average VCL – no statistically significant 
difference. G) Average ALH – no statistically significant difference. H) 
Average % straightness – no statistically significant difference. I) 
Average % linearity – no statistically significant difference. Error bars 
indicate standard error of the mean (SEM). 
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Figure 8.27:  40% sperm cell fraction motility screen using 100µM drug C. No. of donors = 5. Each motility 
parameter was compared in the control (Cont), DMSO and drug C groups at Time 0 minutes (T0), Time 15 minutes (T15) 
and Time 30 minutes (T30).  A) Average % motile cells – no statistically significant difference. B) Average % progressive 
cells – no statistically significant difference. C) Average % rapid cells – no statistically significant difference. D) Average 
VAP – no statistically significant difference. E) Average VCL – no statistically significant difference. F) Average ALH – 
no statistically significant difference. G) Average % straightness – no statistically significant difference. H) Average % 
linearity – no statistically significant difference. Error bars indicate standard error of the mean (SEM). 
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Figure 8.28:  40% sperm cell fraction motility screen using 100µM drug F. No. of donors = 5. Each motility 
parameter was compared in the control (Cont), DMSO and drug F groups at Time 0 minutes (T0), Time 15 minutes 
(T15) and Time 30 minutes (T30). A) Average % motile cells – no statistically significant difference. B) Average % 
progressive cells – no statistically significant difference. C) Average % rapid cells – no statistically significant 
difference. D) Average VAP – no statistically significant difference. E) Average VCL – no statistically significant 
difference. F) Average ALH – no statistically significant difference. G) Average % straightness – no statistically 
significant difference. H) Average % linearity – no statistically significant difference. Error bars indicate standard 
error of the mean (SEM). 
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Figure 8.29:  40% sperm cell fraction motility screen using 100µM drug H. No. of donors = 10. Each motility 
parameter was compared in the control (Cont), DMSO and drug H groups at Time 0 minutes (T0), Time 15 minutes 
(T15) and Time 30 minutes (T30). A) Average % motile cells – no statistically significant difference. B) Average % 
progressive cells – no statistically significant difference. C) Average % rapid cells – no statistically significant 
difference. D) Average VAP – T0: DMSO + drug H - * (P=0.0268). T15+T30: no statistically significant difference. E) 
Average VCL – T0: DMSO + drug H - * (P=0.0436). T15+T30: no statistically significant difference. F) Average ALH 
– no statistically significant difference. G) Average % straightness – no statistically significant difference. H) Average 
% linearity – no statistically significant difference. Error bars indicate standard error of the mean (SEM). 
Figure 8.30:  80% sperm cell fraction motility screen using 
100µM drug C. N = 8. Each motility parameter was compared in the 
control (Cont), DMSO and drug C groups at Time 0 minutes (T0), 
Time 15 minutes (T15) and Time 30 minutes (T30). A) Average % 
rapid cells – no statistically significant difference. B) Average % 
straightness – no statistically significant difference. C) Average % 
linearity – no statistically significant difference. Error bars indicate 
standard error of the mean (SEM). 
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Figure 8.31:  80% sperm cell fraction motility screen using 100µM drug F. N = 8. Each motility parameter was 
compared in the control, DMSO and drug F groups at T0, T15 and T30 control (Cont), DMSO and drug A groups at 
Time 0 minutes (T0), Time 15 minutes (T15) and Time 30 minutes (T30). A) Average % progressive cells – no 
statistically significant difference. B) Average VAP – no statistically significant difference. C) Average % straightness 
– no statistically significant difference. D) Average % linearity – no statistically significant difference. Error bars 
indicate standard error of the mean (SEM). 
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Figure 8.32:  80% sperm cell fraction motility screen using 100µM drug H. N = 8. Each motility parameter was 
compared in the control (Cont), DMSO and drug H groups at Time 0 minutes (T0), Time 15 minutes (T15) and Time 30 
minutes (T30). A) Average % progressive cells – no statistically significant difference. B) Average VAP – no statistically 
significant difference. C) Average VCL – T0: no statistically significant difference. T15: DMSO + drug H - * (P=0.013). 
T30: DMSO + drug H - * (P=0.047) D) Average ALH – T0: no statistically significant difference. T15: DMSO + drug H - * 
(P=0.034). T30: no statistically significant difference. E) Average % straightness – no statistically significant difference. F) 
Average % linearity – no statistically significant difference. Error bars indicate standard error of the mean (SEM). 
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8.3 Kremer test individual donor analysis 
8.3.1 Kremer test drug A-J 30μM screen 
Drug A 30μM: 
 
  
Figure 8.33: Donor cell Kremer screen of drug A 30µM. Cell number is compared using 
ANOVA of control (cont), DMSO, drug and progesterone (prog) treated cells at 1cm and 
2cm. A) D218 1cm: cont. + DMSO - * (P<0.05), DMSO + prog - ** (P = 0.024), prog + drug A - 
* (P<0.05).  2cm: DMSO + prog - * (P<0.05), DMSO + drug A - ** (P=0.0027). B) D272 1cm: 
cont. + prog - *** (P=<0.001), cont. + drug A - ** (P = <0.01), DMSO + prog - *** (p=<0.001), 
DMSO + drug A - *** (P=<0.001), prog + drug A - * (P=<0.05).  2cm: cont. + prog - *** 
(P=<0.001), cont. + drug A - * (P=<0.05), DMSO + prog - *** (P=<0.001), DMSO + drug A - ** 
(P=<0.01), prog + drug A - ** (P=<0.01). C) D093 1cm: cont. + DMSO - * (P=0.0247), cont. + 
prog - * (P=0.024). 2cm: cont. + prog - ** (P=0.0082). D) D258 1cm: no statistically significant 
difference. 2cm: cont. + DMSO - * (P=<0.05), cont. + prog - ** (P=<0.01), DMSO + prog - *** 
(P=<0.001), prog. + drug A - *** (P=<0.001).   
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Drug B 30μM: 
 
Figure 8.34: Donor cell Kremer screen of drug B 30µM. Cell number is compared using ANOVA of control (cont), 
DMSO drug and progesterone (prog) treated cells at 1cm and 2cm. A) D218 1cm: DMSO + prog - * (P=<0.05), prog + 
drug B - * (P=<0.05). 2cm: DMSO + prog - ** (P=<0.01).  B) D180 1cm: cont. + DMSO - * (P=<0.05), cont. + prog - * 
(P=<0.05), cont. vs drug B - * (P=<0.05), DMSO + prog - *** (P=<0.001), prog + drug B - *** (P=<0.001).  2cm: cont. + 
prog - *** (P=<0.001), DMSO + prog - *** (P=<0.001), prog + drug B - *** (P=<0.001). C) D266 1cm + 2cm: no 
statistically significant difference D) D258 1cm: no statistically significant difference 2cm: cont. + DMSO - ** (P=<0.01), 
cont. + prog - ** (P=0.01), cont. + drug B - * (P=<0.05), DMSO + prog - *** (P=<0.001), prog + drug B - *** (P=<0.001). E) 
D093 1cm: cont. + DMSO - * (P=<0.05), cont. + prog - * (P=<0.05).   2cm: cont. + DMSO - ** (P=<0.01), cont. + prog - *** 
(P=<0.001), cont. + drug B - ** (P=<0.01). 
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Drug C 30μM: 
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Figure 8.35: Donor cell Kremer screen of drug C 30µM. Cell number is compared using 
ANOVA of control (cont), DMSO drug and progesterone (prog) treated cells at 1cm and 2cm. 
A) D241 1cm: cont. + drug C - ** (P=<0.01), DMSO + drug C - ** (P=<0.01), prog + drug C - * 
(P=<0.05). 2cm: cont. + drug C - * (P=<0.05), DMSO + drug C - * (P=<0.05). B) D180 1cm: cont. + 
prog - * (P=<0.05), cont. + drug C - ** (P=<0.01), DMSO + prog - *** (P=<0.001), prog + drug C - 
*** (P=<0.001). 2cm: cont. + prog - *** (P=<0.001), DMSO + prog - *** (P=<0.001), prog + drug 
C - *** (P=<0.001). C) D266 1cm + 2cm:  no statistically significant difference. D) D093 1cm: cont. 
+ prog - * (P=<0.05).  2cm: cont. + DMSO - ** (P=<0.01), cont. + prog - *** (P=<0.001), cont. + 
drug C - * (P=<0.05).  E) D266 1cm: cont. + DMSO - * (P=<0.05).  2cm: prog + drug C - * 
(P=<0.05).  F) D123 1cm: no statistically significant difference.  2cm: prog + drug C - * (P=<0.05).   
G) D230 1cm: cont. + prog - ** (P=<0.01), DMSO + prog - *** (P=<0.001), DMSO + drug C - ** 
(P=<0.01).  2cm: cont. + prog - *** (P=<0.001), DMSO + prog - *** (P=0.001), prog + drug C - *** 
(P=0.001). H) D218 1cm: DMSO + drug C - ** (P=<0.01), prog + drug C - ** (P=<0.01). 2cm:  
DMSO + prog - * (P=<0.05), DMSO + drug C - * (P=<0.05). 
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Drug D 30μM: 
 
 
 
  
Figure 8.36: Donor cell Kremer screen of drug D 30µM. Cell number is compared using 
ANOVA of control (cont), DMSO drug and progesterone (prog) treated cells at 1cm and 2cm. 
A) D241 1cm: cont. + drug D - * (P=<0.05), DMSO + drug D - ** (P=<0.01), prog + drug D - ** 
(P=<0.01). 2cm: cont. + drug D - * (P=<0.05), prog + drug D - * (P=<0.05). B) D180 1cm: cont. + 
DMSO - * (P=<0.05), cont. + prog - * (P=<0.05), cont. + drug D - *** (P=<0.001), DMSO + prog - 
*** (P=<0.001), DMSO + drug D *** (P=<0.001), prog + drug D - *** (P=<0.001). 2cm: cont. + 
prog - *** (P=<0.001), cont. + drug D - *** (P=<0.001), DMSO + prog - *** (P=<0.001), DMSO + 
drug D - *** (P=<0.001), prog + drug D - *** (P=<0.001). C) D266 1cm: prog + drug D - * 
(P=<0.05). 2cm: prog + drug D - * (P=<0.05).  
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Drug E 30μM: 
 
  
Figure 8.37: Donor cell Kremer screen of drug E 30µM. Cell number is compared using 
ANOVA of control (cont), DMSO, drug and progesterone (prog) treated cells at 1cm and 2cm.  
A) D241 1cm + 2cm: no statistically significant difference. B) D272 1cm: cont. + prog - *** 
(P=<0.001), DMSO + prog - *** (P=<0.001), prog + drug E - *** (P=<0.001).  2cm: DMSO + prog 
- * (P=<0.05). C) D266 1cm + 2cm: no statistically significant difference.  
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Drug F 30μM: 
 
  
Figure 8.38: Donor cell Kremer screen of drug F 30µM. Cell number is compared using ANOVA of control (cont), 
DMSO, drug and progesterone (prog) treated cells at 1cm and 2cm. A) D169 1cm: cont. + prog - *** (P=<0.001), DMSO 
+ prog - ** (P=<0.01), prog + drug F - ** (P=<0.01).  2cm: No statistically significant difference. B) D272 1cm: cont. + prog 
- ** (P=<0.01), DMSO + prog - *** (P=<0.001), prog + drug F - *** (P=<0.001). 2cm: DMSO + prog - * (P=<0.05). C) 
D266 1cm + 2cm: no statistically significant difference.  
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Drug G 30μM: 
 
 
Figure 8.39: Donor cell Kremer screen of drug G 30µM. Cell number is compared using ANOVA of control (cont), 
DMSO drug and progesterone (prog) treated cells at 1cm and 2cm. A) D169 1cm: cont. + prog - *** (P=<0.001), DMSO 
+ prog - *** (P=<0.001), prog + drug G - *** (P=<0.001). 2cm: No statistically significant difference. B) D266 1cm: cont. + 
drug G - ** (P=<0.01), DMSO + drug G - *(P=<0.05), prog + drug G - ** (P=<0.01).  2cm: No statistically significant 
difference. C) D272 1cm: DMSO + prog - * (P=<0.05). 2cm: cont. + prog - *** (P=<0.001), DMSO + prog - *** (P=<0.001), 
prog + drug G - *** (P=<0.001). D) D266 1cm + 2cm: No statistically significant difference. E) D272 1cm: DMSO + prog - * 
(P=<0.05), prog + drug G - ** (P=<0.01).  2cm: cont. + prog - *** (P=<0.001), DMSO + prog - *** (P=<0.001), prog + drug 
G - *** (P=<0.001).  
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 Drug H 30μM: 
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Figure 8.40: Donor cell Kremer screen of drug H 30µM. Cell number is compared using 
ANOVA of control (cont), DMSO, drug and progesterone (prog) treated cells at 1cm and 2cm. 
A) D169 1cm: cont. + prog - * (P=<0.05), DMSO + prog - * (P=<0.05). 2cm: no statistically 
significant difference. B) D266 1cm: cont. + drug H - ** (P=<0.01), prog + drug H - ** (P=<0.01). 
2cm: DMSO + prog - * (P=<0.05).  C) D272 1cm: cont. + prog - ** (P=<0.01), DMSO + prog - *** 
(P=<0.001), DMSO + drug H - * (P=<0.05), prog + drug H - * (P=<0.05). 2cm: DMSO + prog - ** 
(P=<0.01). D) D218 1cm: cont. + DMSO - * (P=<0.05), DMSO + prog - ** (P=<0.01), DMSO + 
drug H - *** (P=<0.001).  2cm: cont. + prog - *** (P=<0.001), DMSO + prog - *** (P=<0.001), 
DMSO + drug H - * (P=<0.05), prog + drug H - ** (P=<0.01). E) D272 1cm: DMSO + prog - * 
(P=<0.05).  2cm: cont. + prog - *** (P=<0.001), DMSO + prog - *** (P=<0.001), prog + drug H - 
*** (P=<0.001). F) D266 1cm + 2cm: no statistically significant difference.  G) D123 1cm: prog + 
drug H - * (P=<0.05). 2cm: no statistically significant difference. H) D230 1cm: cont. + prog - * 
(P=<0.05), DMSO + prog - *** (P=<0.001). 2cm: cont. + prog - *** (P=<0.001), DMSO + prog - 
*** (P=<0.001), prog + drug H - *** (P=<0.001).  I) D218 1cm: DMSO + drug H - * (P=<0.05), 
prog + drug H - * (P=<0.05). 2cm: DMSO + prog - * (P=<0.05).  
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Drug I 30μM: 
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Figure 8.41: Donor cell Kremer screen of drug I 30µM. Cell number is compared using ANOVA of control (cont), 
DMSO, drug and progesterone (prog) treated cells at 1cm and 2cm. A) D266 1cm: cont. + DMSO - * (P=<0.05), DMSO 
+ drug I - ** (P=<0.01). 2cm: cont. + prog - * (P=<0.05), DMSO + prog - * (P=<0.05), prog + drug I - ** (P=<0.01). B) D272 
1cm: cont. + prog - *** (P=<0.001), cont. + drug I - ** (P=<0.01), DMSO + prog - *** (P=<0.001), prog + drug I - *** 
(P=<0.001).  2cm: cont. + prog - *** (P=<0.001), cont. + drug I - * (P=<0.05), DMSO + prog - *** (P=<0.001), prog + drug I 
- *** (P=<0.001). C) D272 1cm: DMSO + prog - ** (P=<0.01), prog + drug I - * (P=<0.05). 2cm: cont. + prog - *** 
(P=<0.001), DMSO + prog - *** (P=<0.001), prog + drug I- *** (0.001). D) D218 1cm: cont. + DMSO - * (P=<0.05), DMSO 
+ prog - * (P=<0.05), prog + drug I - * (P=<0.05).  2cm: cont. + prog - *** (P=<0.001), DMSO + prog - *** (P=<0.001), prog 
+ drug I - *** (P=<0.001).  E) D272 1cm: cont. + prog - *** (P=<0.001), DMSO + prog - *** (P=<0.001), prog + drug I - 
*** (P=<0.001). 2cm: DMSO + prog - ** (P=<0.01), prog + drug I - ** (P=<0.01).  
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Drug J 30μM: 
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Figure 8.42: Donor cell Kremer screen of drug J 30µM. Cell number is compared using ANOVA of control (cont), 
DMSO, drug and progesterone (prog) treated cells at 1cm and 2cm. A) D218 1cm: cont. + DMSO - * (P=<0.05), cont. + 
drug J - * (P=<0.05), DMSO + prog - ** (P=<0.01), prog + drug J - ** (P=<0.01).  2cm: DMSO + prog - ** (P=<0.01), prog 
+ drug J - * (P=<0.05).  B) D272 1cm: cont. + prog - *** (P=<0.001), DMSO + prog - *** (P=<0.001), prog + drug J - *** 
(P=<0.001).  2cm: cont. + prog - *** (P-<0.001), DMSO + prog - *** (P=<0.001), DMSO + drug J - * (P=<0.05), prog + drug 
J - *** (P=<0.001).  C) D272 1cm: cont. + prog - *** (P=<0.001), DMSO + prog - *** (P=<0.001), prog + drug J - *** 
(P=<0.001).  2cm: DMSO + prog - * (P=<0.05).  D) D218 1cm: cont. + DMSO - * (P=<0.05), DMSO + prog - * (P=<0.05), 
DMSO + drug J - * (P=<0.05). 2cm: cont. + prog - *** (P<0.001), DMSO + prog - *** (P=<0.001), prog + drug J - *** 
(P=<0.001). E) D258 1cm: no statistically significant difference. 2cm: cont. + DMSO - * (P=<0.05), cont. + prog - * 
(P=<0.05), cont. + drug J - * (P=<0.05), DMSO + prog - *** (P=<0.001), prog + drug J - *** (P=<0.001). 
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8.3.2 Kremer test drug C + F 100µM screen 
Drug C 100µM 
 
 
Drug F 100µM 
 
Figure 8.43: Donor cell Kremer screen of drug C 100µM. Cell 
number is compared using ANOVA of control (Cont), drug and 
progesterone (Prog) treated cells at 1cm and 2cm. A) D202 1cm: 
Cont + drug C - * (P<0.05), DMSO + drug C - * (P<0.05), Prog + 
drug C - ** (P=0.0037). 2cm: Cont + Prog - *** (P<0.0001), Cont + 
drug C - * (P<0.05), DMSO + Prog - *** (P<0.0001), Prog + drug C - 
*** (P<0.0001). B) D256 1cm: Cont + DMSO - * (P<0.05), Cont + 
drug C - * (P<0.05). 2cm: Cont + DMSO - * (P<0.05), Cont + drug C 
* (P<0.05), DMSO + Prog - * (P<0.05), Prog + drug C - ** 
(P=0.0031). C) D267 1cm and 2cm: no statistical significance.  
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Figure 8.44: Donor cell Kremer screen of drug F 100µM. Cell 
number is compared using ANOVA of control (Cont), drug and 
progesterone (Prog) treated cells at 1cm and 2cm. A) D202 1cm: no 
statistical significance. 2cm: Cont + Prog - * (P=0.0112), DMSO + 
Prog - * (P=0.0112). B) D267 1cm: Cont + Prog - * (P<0.05), Cont + 
drug F - * (P<0.05). 2cm: no statistical significance. C) D256 1cm: 
Cont + DMSO - ** (P<0.01), Cont + drug F - ** (P<0.01), DMSO + 
Prog - * (P<0.05), Prog + drug F - ** (P<0.01). 2cm: Cont + drug F - 
** (P<0.01), DMSO + Prog - * (P<0.05), Prog + drug F - ** (P<0.01). 
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8.4 Flow cytometry analysis 
8.4.1 A23187 D240  
 
 
8.4.2 DMSO D240  
 
  
Figure 8.45: Flow cytometry analysis after D240 cells were 
incubated with A23187 for 60 minutes. A: FSC plotted against 
SSC: the gated region shows the population of single cells, 
74.6%, from analysis of 10,000 events. B: Single cells: the 
population of single cells gated from the whole cell population 
were plotted as FSC against TO-PRO3 to determine the 
percentage of live and dead cells in the population. 70.9% of 
single cells are live after 60 minutes exposure to DMSO and 
29.1% are dead. C: Acrosome and non-acrosome reacted cells: 
of the population of gated live cells, these were plotted as FITC-
A against TOPRO-3 to determine two cell populations; non-
acrosome reacted, 77.7% and acrosome reacted, 10.8%. TO-
PRO3 and FITC-A are measured in wavelengths of light (nm). 
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8.4.3 Ethanol D240  
 
 
  
Figure 8.46: Flow cytometry analysis after D240 sperm 
were incubated with DMSO for 60 minutes. A: FSC plotted 
against SSC: the gated population of single cells, 56.6% of the 
population of 10,000 events analysed. B: Single cells: the 
population of single cells gated from the whole cell population 
were plotted as FSC against TO-PRO3 to determine the 
percentage of live and dead cells in the sperm cell population. 
76% of the single cells were live after 60 minutes exposure to 
DMSO and 24% were dead. C: Acrosome and non-acrosome 
reacted cells: of the population of gated live cells, these were 
plotted as FITC-A against TO-PRO3 to determine two cell 
populations; non-acrosome reacted, 74.6% and acrosome 
reacted, 2.53%. TO-PRO3 and FITC-A are measured in 
wavelengths of light (nm). 
Figure 8.47: Flow cytometry analysis after D240 sperm were 
incubated with ethanol for 60 minutes. A: FSC plotted against SSC: 
the gated population of single cells, 53.8% of the population of 10,000 
events analysed. B: Single cells: the population of single cells gated 
from the whole cell population were plotted as FSC + TO-PRO3 to 
determine the percentage of live and dead cells in the sperm cell 
population. 73.8% of the single cells were live after 60 minutes 
exposure to ethanol and 26.2% were dead. C: Acrosome and non-
acrosome reacted cells: of the population of gated live cells, these 
were plotted as FITC-A against TO-PRO3 to determine two cell 
populations; non-acrosome reacted, 67.8% and acrosome reacted, 
4.13%. TO-PRO3 and FITC-A are measured in wavelengths of light 
(nm). 
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8.4.4 Drug A D240  
 
 
 
  
Figure 8.48: Flow cytometry analysis after D240 sperm 
was incubated with drug A for 60 minutes. A: FSC 
plotted against SSC: the gated population are single cells, 
58% of the population of 10,000 events analysed. B: Single 
cells: these cells were then plotted as FSC against TO-
PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, 
the dead cells (25.1%) and live cells (74.9%). C: Acrosome 
and non-acrosome reacted cells: the live cells were plotted 
as FITC-A against TO-PRO3 to determine two cell 
populations, non-acrosome reacted, 79.2% and acrosome 
reacted, 2.07%. D: Histogram comparing live drug A 
treated acrosome and non-acrosome reacted cells with 
DMSO, ethanol and calcium ionophore treated cells from 
the same sample. 
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8.4.5 Drug B D240 
 
 
 
 
 
Figure 8.49: Flow cytometry analysis after D240 sperm was 
incubated with drug B for 60 minutes. A: FSC plotted against SSC: 
the gated population are single cells, 56.4% of the population of 
10,000 events analysed. B: Single cells: these cells were then plotted 
as FSC against TO-PRO3 to determine the percentage of live and 
dead cells in the single cells. Cells are split into two clear 
populations, the dead cells (27.3%) and live cells (72.7%). C: 
Acrosome and non-acrosome reacted cells: the gated live cells were 
plotted as FITC-A against TO-PRO3 to determine two cell 
populations, non-acrosome reacted, 79% and acrosome reacted, 
1.32%. D: Histogram comparing live drug B treated acrosome and 
non-acrosome reacted cells with DMSO, ethanol and calcium 
ionophore treated cells from the same sample. 
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8.4.6 Drug C D240  
 
 
 
  
Figure 8.50: Flow cytometry analysis after D240 sperm was 
incubated with drug C for 60 minutes. A: FSC plotted against 
SSC: the gated population are single cells, 54.2% of the population 
of 10,000 events analysed. B: Single cells: these cells were then 
plotted as FSC against TO-PRO3 to determine the percentage of 
live and dead cells in the single cell population. Cells are split into 
two clear populations, the dead cells (30%) and live cells (70%). C: 
Acrosome and non-acrosome reacted cells: the gated live cells were 
plotted as FITC-A against TO-PRO3 to determine two cell 
populations, non-acrosome reacted, 78.6% and acrosome reacted, 
1.42%. D: Histogram comparing live drug C treated acrosome and 
non-acrosome reacted cells with DMSO, ethanol and calcium 
ionophore treated cells from the same sample. 
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8.4.7 Drug D D240 
 
 
 
 
 
 
Figure 8.51: Flow cytometry analysis after D240 sperm was 
incubated with drug D for 60 minutes. A: FSC plotted against SSC: 
the gated population are single cells, 74% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cell population. Cells are split into two clear populations, the 
dead cells (95.7%) and live cells (4.33%). C: Acrosome and non-
acrosome reacted cells: the gated live cells were plotted as FITC-A 
against TO-PRO3 to determine two cell populations, non-acrosome 
reacted, 19.9% and acrosome reacted, 1.25%. D: Histogram comparing 
live drug D treated acrosome and non-acrosome reacted cells with 
DMSO, ethanol and calcium ionophore treated cells from the same 
sample. 
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8.4.8 Drug E D240  
 
 
 
 
 
 
 
Figure 8.52: Flow cytometry analysis after D240 sperm was 
incubated with drug E for 60 minutes. A: FSC plotted against 
SSC: the gated population are single cells, 60.4% of the 
population of 10,000 events analysed. B: Single cells: these cells 
were then plotted as FSC against TO-PRO3 to determine the 
percentage of live and dead cells in the sperm cell population. 
Cells are split into two clear populations, the dead cells (29.8%) 
and live cells (70.2%). C: Acrosome and non-acrosome reacted 
cells: the gated live cells were plotted as FITC-A against TO-
PRO3 to determine two cell populations, non-acrosome reacted, 
81.7% and acrosome reacted, 1.2%. D: Histogram comparing 
live drug E treated acrosome and non-acrosome reacted cells 
with DMSO, ethanol and calcium ionophore treated cells from 
the same sample. 
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8.4.9 A23187 D180  
                  
    
 
8.4.10 DMSO D180  
          
 
 
 
 
 
Figure 8.53: Flow cytometry analysis after D180 cells were 
incubated with A23187 for 60 minutes. A: FSC plotted against 
SSC: the gated region shows the population of single cells, 70.1%, 
from analysis of 10,000 events. B: Single cells: the population of 
single cells gated from the whole cell population were plotted as 
FSC against TO-PRO3 to determine the percentage of live and 
dead cells in the population. 25.2% of single cells are live after 60 
minutes exposure to DMSO and 74.7% are dead. C: Acrosome and 
non-acrosome reacted cells: of the population of gated live cells, 
these were plotted as FITC-A against TOPRO-3 to determine two 
cell populations; non-acrosome reacted, 57.2% and acrosome 
reacted, 33.7%. TO-PRO3 and FITC-A are measured in 
wavelengths of light (nm). 
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8.4.11 Ethanol D180  
               
       
  
Figure 8.54: Flow cytometry analysis after D180 sperm were 
incubated with DMSO for 60 minutes. A: FSC plotted against SSC: 
the gated population of single cells, 42.8% of the population of 10,000 
events analysed. B: Single cells: the population of single cells gated 
from the whole cell population were plotted as FSC against TO-PRO3 
to determine the percentage of live and dead cells in the sperm cell 
population. 74.6% of the single cells were live after 60 minutes 
exposure to DMSO and 25.4% were dead. C: Acrosome and non-
acrosome reacted cells: of the population of gated live cells, these were 
plotted as FITC-A against TO-PRO3 to determine two cell populations; 
non-acrosome reacted, 84.4% and acrosome reacted, 3.32%. TO-PRO3 
and FITC-A are measured in wavelengths of light (nm). 
Figure 8.55: Flow cytometry analysis after D180 sperm were 
incubated with ethanol for 60 minutes. A: FSC plotted against 
SSC: the gated population of single cells, 38.2% of the 
population of 10,000 events analysed. B: Single cells: the 
population of single cells gated from the whole cell population 
were plotted as FSC against TO-PRO3 to determine the 
percentage of live and dead cells in the sperm cell population. 
68.9% of the single cells were live after 60 minutes exposure to 
ethanol and 30.9% were dead. C: Acrosome and non-acrosome 
reacted cells: of the population of gated live cells, these were 
plotted as FITC-A against TO-PRO3 to determine two cell 
populations; non-acrosome reacted, 77.7% and acrosome reacted, 
4.75%. TO-PRO3 and FITC-A are measured in wavelengths of 
light (nm). 
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8.4.12 Drug F D180 
         
     
 
 
 
 
Figure 8.56: Flow cytometry analysis after D180 sperm was 
incubated with drug F for 60 minutes. A: FSC plotted against 
SSC: the gated population are single cells, 43.2% of the population 
of 10,000 events analysed. B: Single cells: these cells were then 
plotted as FSC against TO-PRO3 to determine the percentage of 
live and dead cells in the single cell population. Cells are split into 
two clear populations, the dead cells (30.5%) and live cells 
(69.4%). C: Acrosome and non-acrosome reacted cells: the gated 
live cells were plotted as FITC-A against TO-PRO3 to determine 
two cell populations, non-acrosome reacted, 83.9% and acrosome 
reacted, 1.84%. D: Histogram comparing live drug F treated 
acrosome and non-acrosome reacted cells with DMSO, Ethanol 
and calcium ionophore treated cells from the same sample. 
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Figure 8.57: Flow cytometry analysis after D180 sperm was 
incubated with drug G for 60 minutes. A: FSC plotted against 
SSC. The gated population are single cells, 71.8% of the 
population of 10,000 events analysed. B: Single cells: these cells 
were then plotted as FSC against TO-PRO3 to determine the 
percentage of live and dead cells in the single cell population. 
Cells are split into two clear populations, the dead cells (100%) 
and live cells (0%). C: Acrosome and non-acrosome reacted 
cells: the gated live cells were plotted as FITC-A against TO-
PRO3 to determine two cell populations, non-acrosome reacted, 
0% and acrosome reacted, 0%. D: Histogram comparing live 
drug G treated acrosome and non-acrosome reacted cells with 
DMSO, Ethanol and calcium ionophore treated cells from the 
same sample. 
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Figure 8.58: Flow cytometry analysis after D180 sperm was 
incubated with drug H for 60 minutes. A: FSC plotted against 
SSC. The gated population are single cells, 48.2% of the 
population of 10,000 events analysed. B: Single cells: these cells 
were then plotted as FSC against TO-PRO3 to determine the 
percentage of live and dead cells in the single cells. Cells are split 
into two clear populations, the dead cells (29.9%) and live cells 
(70%). C: Acrosome and non-acrosome reacted cells: the gated 
live cells were plotted as FITC-A against TO-PRO3 to determine 
two cell populations, non-acrosome reacted, 90% and acrosome 
reacted, 0.799%. D: Histogram comparing live drug H treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol 
and calcium ionophore treated cells from the same sample. 
A 
B 
C 
D 
71 
 
8.4.15 Drug I D180 
           
     
 
  
Figure 8.59: Flow cytometry analysis after D180 sperm was 
incubated with drug I for 60 minutes. A: FSC plotted against SSC: 
the gated population are single cells, 70.8% of the population of 
10,000 events analysed. B: Single cells: these cells were then plotted 
as FSC against TO-PRO3 to determine the percentage of live and 
dead cells in the sperm cell population. Cells are split into two clear 
populations, the dead cells (45.8%) and live cells (54.1%). C: 
Acrosome and non-acrosome reacted cells: the gated live cells were 
plotted as FITC-A against TO-PRO3 to determine two cell 
populations, non-acrosome reacted, 92% and acrosome reacted, 
1.38%. D: Histogram comparing live drug I treated acrosome and 
non-acrosome reacted cells with DMSO, ethanol and calcium 
ionophore treated cells from the same sample. 
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Figure 8.60: Flow cytometry analysis after D180 sperm was 
incubated with drug J for 60 minutes. A: FSC plotted against SSC: 
the gated population are single cells, 47.7% of the population of 
10,000 events analysed. B: Single cells: these cells were then plotted 
as FSC against TO-PRO3 to determine the percentage of live and 
dead cells in the sperm cell population. Cells are split into two clear 
populations, the dead cells (27.5%) and live cells (72.5%). C: 
Acrosome and non-acrosome reacted cells: the gated live cells were 
plotted as FITC-A against TO-PRO3 to determine two cell 
populations, non-acrosome reacted, 91% and acrosome reacted, 
0.665%. D: Histogram comparing live drug J treated acrosome and 
non-acrosome reacted cells with DMSO, ethanol and calcium 
ionophore treated cells from the same sample. 
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Figure 8.61: Flow cytometry analysis after D093 sperm were 
incubated with A23187 for 60 minutes. A: FSC plotted against 
SSC: the gated region shows the population are single cells, 86.3% 
from analysis of 10,000 events analysed. B: Single cells: the 
population of single cells gated from the whole cell population were 
plotted as FSC against TO-PRO3 to determine the percentage of live 
and dead cells in the population. 65.4% of single cells are live after 
60 minutes exposure to A23187 and 34.6% are dead. C: Acrosome 
and non-acrosome reacted cells: of the population of gated live cells, 
these were plotted as FITC-A against TO-PRO3 to determine two 
cell populations; non-acrosome reacted, 54.6% and acrosome 
reacted, 40.3%. TO-PRO3 and FITC-A are measured in wavelengths 
of light (nm). 
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Figure 8.62: Flow cytometry analysis after D093 sperm were 
incubated with DMSO for 60 minutes. A: FSC plotted against 
SSC: the gated population of single cells, 75.6% of the population 
of 10,000 events analysed. B: Single cells: the population of 
single cells gated from the whole cell population were plotted as 
FSC against TO-PRO3 to determine the percentage of live and 
dead cells in the sperm cell population. 84.1% of the single cells 
were live after 60 minutes exposure to DMSO and 15.9% were 
dead. C: Acrosome and non-acrosome reacted cells: of the 
population of gated live cells, these were plotted as FITC-A 
against TO-PRO3 to determine two cell populations; non-
acrosome reacted, 94.3% and acrosome reacted, 0.692%. TO-
PRO3 and FITC-A are measured in wavelengths of light (nm). 
Figure 8.63: Flow cytometry analysis after D093 sperm were 
incubated with ethanol for 60 minutes. A: FSC plotted against 
SSC: the gated population of single cells, 69.8% of the population 
of 10,000 events analysed. B: Single cells: the population of single 
cells gated from the whole cell population were plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells 
in the sperm cell population. 82.1% of the single cells were live 
after 60 minutes exposure to ethanol and 17.9% were dead. C: 
Acrosome and non-acrosome reacted cells: of the population of 
gated live cells, these were plotted as FITC-A against TO-PRO3 to 
determine two cell populations; non-acrosome reacted, 93.3% and 
acrosome reacted, 1.29%. TO-PRO3 and FITC-A are measured in 
wavelengths of light (nm). 
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Figure 8.64: Flow cytometry analysis after D093 sperm was 
incubated with drug A for 60 minutes. A: FSC plotted against SSC: 
the gated population are single cells, 72.6% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(18.1%) and live cells (81.9%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 94.6% and 
acrosome reacted, 1.33%. D: Histogram comparing live drug A treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells from the same sample. 
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Figure 8.65: Flow cytometry analysis after D093 sperm was 
incubated with drug B for 60 minutes. A: FSC plotted against SSC: the 
gated population are single cells, 72.1% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(24.1%) and live cells (75.9%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 93.6% and 
acrosome reacted, 1.1%. D: Histogram comparing live drug B treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells of the same sample. 
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Figure 8.66: Flow cytometry analysis after D093 sperm was 
incubated with drug C for 60 minutes. A: FSC plotted against SSC: 
the gated population are single cells, 65.2% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(24.7%) and live cells (75.3%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 93.7% and 
acrosome reacted, 1.49%. D: Histogram comparing live drug C treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells from the same sample. 
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Figure 8.67: Flow cytometry analysis after D226 sperm was 
incubated with drug D for 60 minutes. A: FSC plotted against SSC: 
the gated population are single cells, 79.1% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(85.4%) and live cells (14.6%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 74.5% and 
acrosome reacted, 2.51%. D: Histogram comparing live drug D treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells from the same sample. 
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Figure 8.68: Flow cytometry analysis after D093 sperm was 
incubated with drug E for 60 minutes. A: FSC plotted against SSC: the 
gated population are single cells, 70.2% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(28%) and live cells (72%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 92.3% and 
acrosome reacted, 1.88%. D: Histogram comparing live drug E treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells from the same sample. 
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Figure 8.69: Flow cytometry analysis after D230 sperm were 
incubated with A23187 for 60 minutes. A: FSC plotted against SSC: 
the gated region shows the population are single cells, 64.7% from 
analysis of 10,000 events analysed. B: Single cells: the population of 
single cells gated from the whole cell population were plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells 
in the population. 64.5% of single cells are live after 60 minutes 
exposure to A23187 and 35.5% are dead. C: Acrosome and non-
acrosome reacted cells: of the population of gated live cells, these 
were plotted as FITC-A against TO-PRO3 to determine two cell 
populations; non-acrosome reacted, 75.8% and acrosome reacted, 
11.6%. TO-PRO3 and FITC-A are measured in wavelengths of light 
(nm). 
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Figure 8.70: Flow cytometry analysis after D230 sperm were 
incubated with DMSO for 60 minutes. A: FSC plotted against SSC: 
the gated population of single cells, 54.8% of the population of 10,000 
events analysed. B: Single cells: the population of single cells gated 
from the whole cell population were plotted as FSC against TO-PRO3 
to determine the percentage of live and dead cells in the sperm cell 
population. 70.4% of the single cells were live after 60 minutes 
exposure to DMSO and 29.6% were dead. C: Acrosome and non-
acrosome reacted cells: of the population of gated live cells, these were 
plotted as FITC-A against TO-PRO3 to determine two cell populations; 
non-acrosome reacted, 72.4% and acrosome reacted, 2.26%. TO-PRO3 
and FITC-A are measured in wavelengths of light (nm). 
Figure 8.71: Flow cytometry analysis after D230 sperm were 
incubated with ethanol for 60 minutes. A: FSC plotted against SSC: 
the gated population of single cells, 49.7% of the population of 10,000 
events analysed. B: Single cells: the population of single cells gated 
from the whole cell population were plotted as FSC against TO-PRO3 
to determine the percentage of live and dead cells in the sperm cell 
population. 66.5% of the single cells were live after 60 minutes 
exposure to ethanol and 33.5% were dead. C: Acrosome and non-
acrosome reacted cells: of the population of gated live cells, these 
were plotted as FITC-A against TO-PRO3 to determine two cell 
populations; non-acrosome reacted, 74.2% and acrosome reacted, 
2.27%. TO-PRO3 and FITC-A are measured in wavelengths of light 
(nm). 
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Figure 8.72: Flow cytometry analysis after D230 sperm was 
incubated with drug F for 60 minutes. A: FSC plotted against SSC: the 
gated population are single cells, 55.3% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(37.3%) and live cells (62.7%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 75.5% and 
acrosome reacted, 3.23%. D: Histogram comparing live drug E treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells from the same sample. 
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Figure 8.73: Flow cytometry analysis after D230 sperm was 
incubated with drug G for 60 minutes. A: FSC plotted against SSC: 
the gated population are single cells, 74.6% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(100%) and live cells (0%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 0% and acrosome 
reacted, 0%. D: Histogram comparing live drug G treated acrosome and 
non-acrosome reacted cells with DMSO, ethanol and calcium ionophore 
treated cells from the same sample. 
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Figure 8.74: Flow cytometry analysis after D230 sperm was 
incubated with drug H for 60 minutes. A: FSC plotted against SSC: 
the gated population are single cells, 59.3% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(25.2%) and live cells (74.8%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 84.9% and 
acrosome reacted, 0.924%. D: Histogram comparing live drug H treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells from the same sample. 
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Figure 8.75: Flow cytometry analysis after D230 sperm was 
incubated with drug I for 60 minutes. A: FSC plotted against SSC: the 
gated population are single cells, 61.7% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(36.1%) and live cells (63.9%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 86.4% and 
acrosome reacted, 1.04%. D: Histogram comparing live drug I treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells from the same sample. 
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Figure 8.76: Flow cytometry analysis after D230 sperm was 
incubated with drug J for 60 minutes. A: FSC plotted against SSC: the 
gated population are single cells, 59% of the population of 10,000 events 
analysed. B: Single cells: these cells were then plotted as FSC against 
TO-PRO3 to determine the percentage of live and dead cells in the single 
cells. Cells are split into two clear populations, the dead cells (27.8%) 
and live cells (72.2%). C: Acrosome and non-acrosome reacted cells: the 
live cells were plotted as FITC-A against TO-PRO3 to determine two 
cell populations, non-acrosome reacted, 82.4% and acrosome reacted, 
1.76%. D: Histogram comparing live drug J treated acrosome and non-
acrosome reacted cells with DMSO, ethanol and calcium ionophore 
treated cells from the same sample. 
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Figure 8.77: Flow cytometry analysis after D218 sperm were 
incubated with A23187 for 60 minutes. A: FSC plotted against 
SSC: the gated region shows the population are single cells, 57% 
from analysis of 10,000 events analysed. B: Single cells: the 
population of single cells gated from the whole cell population 
were plotted as FSC against TO-PRO3 to determine the percentage 
of live and dead cells in the population. 73.5% of single cells are 
live after 60 minutes exposure to DMSO and 26.5% are dead. C: 
Acrosome and non-acrosome reacted cells: of the population of 
gated live cells, these were plotted as FITC-A against TO-PRO3 to 
determine two cell populations; non-acrosome reacted, 84.9% and 
acrosome reacted, 4.63%. TO-PRO3 and FITC-A are measured in 
wavelengths of light (nm). 
A B 
C 
A B 
88 
 
 
8.4.35 Ethanol D218  
         
     
  
Figure 8.78: Flow cytometry analysis after D226 sperm were 
incubated with DMSO for 60 minutes. A: FSC plotted against 
SSC: the gated population of single cells, 48.8% of the population of 
10,000 events analysed. B: Single cells: the population of single cells 
gated from the whole cell population were plotted as FSC against 
TO-PRO3 to determine the percentage of live and dead cells in the 
sperm cell population. 69.5% of the single cells were live after 60 
minutes exposure to DMSO and 30.6% were dead. C: Acrosome and 
non-acrosome reacted cells: of the population of gated live cells, 
these were plotted as FITC-A against TO-PRO3 to determine two 
cell populations; non-acrosome reacted, 82.2% and acrosome 
reacted, 0.914%. TO-PRO3 and FITC-A are measured in 
wavelengths of light (nm). 
Figure 8.79: Flow cytometry analysis after D218 sperm were 
incubated with ethanol for 60 minutes. A: FSC plotted against SSC: 
the gated population of single cells, 52.2% of the population of 10,000 
events analysed. B: Single cells: the population of single cells gated 
from the whole cell population were plotted as FSC against TO-PRO3 
to determine the percentage of live and dead cells in the sperm cell 
population. 73.8% of the single cells were live after 60 minutes 
exposure to ethanol and 26.2% were dead. C: Acrosome and non-
acrosome reacted cells: of the population of gated live cells, these 
were plotted as FITC-A against TO-PRO3 to determine two cell 
populations; non-acrosome reacted, 89.9% and acrosome reacted, 
0.338%. TO-PRO3 and FITC-A are measured in wavelengths of light 
(nm). 
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Figure 8.80: Flow cytometry analysis after D218 sperm was 
incubated with drug F for 60 minutes. A: FSC plotted against SSC: the 
gated population are single cells, 47.3% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(39%) and live cells (61%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 87.5% and 
acrosome reacted, 1.01%. D: Histogram comparing live drug F treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells from the same sample. 
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Figure 8.81: Flow cytometry analysis after D218 sperm was 
incubated with drug G for 60 minutes. A: FSC plotted against SSC: 
the gated population are single cells, 68.4% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(100%) and live cells (0%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 0% and acrosome 
reacted, 0%. D: Histogram comparing live drug G treated acrosome and 
non-acrosome reacted cells with DMSO, ethanol and calcium ionophore 
treated cells from the same sample. 
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Figure 8.82: Flow cytometry analysis after D218 sperm was 
incubated with drug H for 60 minutes. A: FSC plotted against SSC: 
the gated population are single cells, 48.9% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(41.5%) and live cells (58.5%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 85.5% and 
acrosome reacted, 0.525%. D: Histogram comparing live drug H treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells from the same sample. 
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Figure 8.83: Flow cytometry analysis after D218 sperm was 
incubated with drug I for 60 minutes. A: FSC plotted against SSC: the 
gated population are single cells, 54.8% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(44.9%) and live cells (55.1%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 87.8% and 
acrosome reacted, 1.13%. D: Histogram comparing live drug I treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells from the same sample. 
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Figure 8.84: Flow cytometry analysis after D218 sperm was 
incubated with drug J for 60 minutes. A: FSC plotted against SSC: the 
gated population are single cells, 48.3% of the population of 10,000 
events analysed. B: Single cells: these cells were then plotted as FSC 
against TO-PRO3 to determine the percentage of live and dead cells in 
the single cells. Cells are split into two clear populations, the dead cells 
(39.5%) and live cells (60.5%). C: Acrosome and non-acrosome reacted 
cells: the live cells were plotted as FITC-A against TO-PRO3 to 
determine two cell populations, non-acrosome reacted, 86.5% and 
acrosome reacted, 0.957%. D: Histogram comparing live drug J treated 
acrosome and non-acrosome reacted cells with DMSO, ethanol and 
calcium ionophore treated cells from the same sample. 
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Figure 8.85: IVF patient R1724 Kremer screen using 30µM 
drug C + F. Cell number is compared using ANOVA of control 
(cont), drug and progesterone (prog) treated cells at 1cm and 2cm. 
1cm: no significant difference. 2cm: Drug C + Prog - * 
(P=0.0268).  
Figure 8.86: IVF patient R1725 Kremer screen using 30µM 
drug C + F. Cell number is compared using ANOVA of control 
(cont), drug and progesterone (prog) treated cells at 1cm and 
2cm. 1cm: Drug C + Prog - * (P<0.05). 2cm: no significant 
difference.  
 
Figure 8.87: IVF patient R1730 Kremer screen using 
30µM drug C + F. Cell number is compared using ANOVA 
of control (cont), drug and progesterone (prog) treated cells at 
1cm and 2cm. 1cm: Cont + Drug C - * (P=0.0291), Cont + 
Drug F - ** (P=0.0085). 2cm: no significant difference.  
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Figure 8.88: IVF patient R1734 Kremer screen using 30µM 
drug C + F. Cell number is compared using ANOVA of 
control (cont), drug and progesterone (prog) treated cells at 
1cm and 2cm. 1cm: no significant difference. 2cm: Cont + 
Prog - * (P<0.05), Drug C + Prog - * (P<0.05), Cont + Drug F 
- * (P=0.0133).  
 
Figure 8.89: IVF patient R1770 Kremer screen using 30µM 
drug C + F. Cell number is compared using ANOVA of 
control (cont), drug and progesterone (prog) treated cells at 
1cm and 2cm. 1cm: no significant difference. 2cm: no 
significant difference.  
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8.6 Consent form for patient/donor participation in research 
 
CONSENT FORM FOR PATIENTS/DONORS  
[producing extra semen samples]   
Title of research: Understanding the regulation of human sperm function and the development of novel treatments for 
male infertility. 
First of all we would like to thank you very much for taking part in our research project. 
The aim of this study is to understand how a sperm cell is activated in response to secretions from the female tract - 
progesterone and nitric oxide and to understand if this activation is abnormal in some men. In addition we would like to 
test enzyme inhibitors to see if we can enhance sperm motility and hope that in the future we may be able to develop 
drugs which may be able to improve IVF success. 
You may decline to take part, or withdraw at any time without this affecting, in any way, your treatment and care now 
or in the future. 
I have fully understood what will be involved in the project.  This study involves me producing a semen (sperm) sample 
by masturbation in the Assisted Conception Unit or by arrangement at home, for the research purposes of the project.  
In the future there may be requests for further semen samples. 
 
Signed……………………………………………………………………………………. 
Name (block capitals)…………………………………………………………………….. 
Date………………………………………………………………………………………… 
Witnessed…………………………………(name)………………………………Signature 
 
If you have any further queries or questions you can contact either: Mr Steven Mansell (01382 660111 ext. 33605) or 
Nurse Evelyn Barratt,  e.barratt@dundee.ac.uk 
 
  
ASSISTED CONCEPTION 
UNIT 
NHS TAYSIDE 
WARD 35 NINEWELLS HOSPITAL 
 DUNDEE DD1 9SY 
 
 Direct line (01382) 632111 
Fax (01382) 633853 
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Patient/donor consent form 
Research to improve our understanding of how human sperm function 
I have read the research study information sheet and have had the opportunity to ask questions                                                                                 
YES / NO                                                                                
I understand that I can withdraw consent or change my mind at any time 
                                                                                                         YES / NO 
Whether I participate or not, I understand that this will have no impact on my treatment or care 
either now or in the future                YES / NO 
I consent to allowing researchers to use left-over semen following diagnosis or treatment   
        YES / NO 
I am prepared to be contacted for a further sample, if required     YES / NO 
If yes: contact details 
 
SIGNED………………………………………………………………………………………………………………………….. 
NAME (BLOCK CAPITALS)……………………………………………………………………………………….. 
DATE…………………………………………………………………………………….. 
WITNESSED……………………………………(NAME)……………………………………(SIGNATURE) 
If you have any further questions or queries you can contact either nurse Evelyn Barratt (07528 
558624 or email e.barratt@dundee.ac.uk) or Dr Sarah Martins da Silva (01382 660111 bleep 4535 or 
email s.martinsdasilva@dundee.ac.uk)  
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